Latest Period
Q2 2026
Security Snapshot
C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CCCC) Institutional Ownership
CUSIP: 12529R107
13F Institutional Holders and Ownership History from Q4 2020 to Q2 2026
Institutions Reporting
147
Shares (Excl. Options)
117,636,150
Price
$4.67
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- CCCC on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 117,636,150
- Total 13F value
- $547,696,840
- Portfolio coverage rank
- 0%
- Share change
- +33,275,185
- Value change
- +$159,616,661
- Number of holders
- 147
- Shares outstanding
- 110,144,928
- SEC-reported price per share
- $3.58
- Insider filing price
- $3.58
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CCCC - C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 12529R107.
- 147 institutions reported positions in Q2 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 122 to 147 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $221,300,312 to $547,696,840.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 147 institutions filings for Q2 2026.
Security key
12529R107
Latest holder period
Q2 2026
13F holders
147
13D/G owners
11
CIK / CUSIP context first
Open Q2 2026 holders
CCCC full holder history
C4 Therapeutics, Inc. SEC filings
C4 Therapeutics, Inc. company facts
C4 Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 12529R107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
CCCC
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sirenia Capital Management LP | 9.9% | $59,702,700 | 23,505,000 | Sirenia Capital Management LP | 31 Mar 2026 | |||
| Lynx1 Capital Management LP | 10% | +38% | $66,167,634 | +$35,716,644 | 15,423,691 | +117% | Lynx1 Capital Management LP | 30 Jun 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $48,836,056 | +$8,333,068 | 11,383,696 | +21% | RA Capital Management, L.P. | 30 Jun 2026 |
| Soleus Capital Master Fund, L.P. | 10% | $19,791,153 | 10,361,860 | Soleus Capital Master Fund, L.P. | 31 Dec 2025 | |||
| MORGAN STANLEY | 8% | -14% | $38,017,989 | -$481,291 | 8,862,002 | -1.3% | Morgan Stanley | 30 Jun 2026 |
| BlackRock, Inc. | 6.9% | +147% | $35,860,491 | +$27,657,108 | 7,678,906 | +337% | BlackRock, Inc. | 30 Jun 2026 |
| Squadron Capital Management LLC | 6.9% | +38% | $32,604,000 | +$8,794,500 | 7,600,000 | +37% | Squadron Master Fund LP | 30 Jun 2026 |
| Bain Capital Life Sciences Fund II, L.P. | 6.2% | $13,453,200 | 6,060,000 | BCLS II Equity Opportunities, LP | 17 Oct 2025 | |||
| WASATCH ADVISORS LP | 6.8% | -34% | $10,773,085 | -$5,817,712 | 4,852,741 | -35% | Wasatch Advisors LP | 30 Sep 2025 |
| ORBIMED ADVISORS LLC | 1% | -80% | $1,687,550 | -$5,127,991 | 883,534 | -75% | OrbiMed Capital LLC | 31 Dec 2025 |
| Point72 Asset Management, L.P. | 0.2% | -97% | $429,504 | -$57,095,520 | 169,096 | -99% | Point72 Asset Management, L.P. | 31 Mar 2026 |
As of 30 Jun 2026, 147 institutional investors reported holding 117,636,150 shares of C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CCCC). This represents 107% of the company’s total 110,144,928 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
89%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | 8.1% | 8,867,338 | -2.3% | 0% | $41,410,468 |
| RA CAPITAL MANAGEMENT, L.P. | 7.3% | 8,000,000 | 0% | 0.32% | $37,360,000 |
| BlackRock, Inc. | 7.2% | 7,896,718 | +285% | 0% | $36,877,672 |
| Lynx1 Capital Management LP | 6.7% | 7,326,691 | +4.7% | 4% | $34,215,647 |
| Squadron Capital Management LLC | 6.5% | 7,200,000 | +220% | 12% | $33,624,000 |
| Bain Capital Life Sciences Investors, LLC | 6.5% | 7,171,910 | 0% | 2% | $33,492,820 |
| JPMORGAN CHASE & CO | 4.3% | 4,747,424 | +47% | 0% | $20,651,295 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 4,417,731 | +14% | 0% | $20,630,804 |
| CITADEL ADVISORS LLC | 3.8% | 4,187,580 | +67% | 0.01% | $19,555,999 |
| GOLDMAN SACHS GROUP INC | 3.2% | 3,530,991 | +48% | 0% | $16,489,728 |
| WASATCH ADVISORS LP | 3.2% | 3,522,644 | +19% | 0.11% | $16,450,747 |
| TWO SIGMA INVESTMENTS, LP | 3.2% | 3,469,707 | +14% | 0.01% | $16,203,532 |
| Soleus Capital Management, L.P. | 3.1% | 3,377,981 | -11% | 0.54% | $15,775,171 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.8% | 3,032,060 | +59% | 1.6% | $14,159,720 |
| BANK OF AMERICA CORP /DE/ | 2.4% | 2,656,359 | +13% | 0% | $12,405,197 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 2,522,163 | +165% | 0% | $11,780,697 |
| Ikarian Capital, LLC | 2.2% | 2,433,000 | 1.9% | $11,362,110 | |
| STATE STREET CORP | 1.9% | 2,115,621 | +452% | 0% | $9,879,950 |
| ACADIAN ASSET MANAGEMENT LLC | 1.6% | 1,806,199 | -4.5% | 0.01% | $8,429,000 |
| Candriam S.C.A. | 1.6% | 1,796,937 | 0.04% | $8,383,622 | |
| D. E. Shaw & Co., Inc. | 1.6% | 1,740,989 | +64% | 0.01% | $8,130,419 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.6% | 1,732,210 | +35% | 0.01% | $8,089,421 |
| Patient Square Capital LP | 1.5% | 1,608,815 | 1.2% | $7,513,166 | |
| HighVista Strategies LLC | 1.2% | 1,348,136 | 1.4% | $6,295,800 | |
| RENAISSANCE TECHNOLOGIES LLC | 1.1% | 1,189,828 | -52% | 0.01% | $5,556,497 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
Q2 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 117,636,150 | $547,696,840 | +$159,616,661 | $4.67 | 147 |
| 2026 Q1 | 84,491,097 | $221,300,312 | +$11,954,068 | $2.63 | 122 |
| 2025 Q4 | 79,828,313 | $152,468,758 | +$51,887,612 | $1.91 | 101 |
| 2025 Q3 | 52,538,995 | $116,636,299 | -$3,450,925 | $2.22 | 96 |
| 2025 Q2 | 54,715,914 | $78,242,864 | -$14,672,718 | $1.43 | 102 |
| 2025 Q1 | 64,100,740 | $102,562,013 | -$12,577,745 | $1.60 | 113 |
| 2024 Q4 | 64,400,415 | $231,841,449 | -$9,805,080 | $3.60 | 113 |
| 2024 Q3 | 64,180,724 | $365,858,667 | +$21,073,945 | $5.70 | 118 |
| 2024 Q2 | 60,887,928 | $281,302,982 | +$5,545,189 | $4.62 | 114 |
| 2024 Q1 | 58,201,499 | $475,505,218 | +$93,890,692 | $8.17 | 104 |
| 2023 Q4 | 47,001,017 | $265,585,658 | +$85,422,229 | $5.65 | 91 |
| 2023 Q3 | 34,671,251 | $64,488,483 | -$134,435 | $1.86 | 82 |
| 2023 Q2 | 34,220,399 | $94,120,957 | -$9,383,233 | $2.75 | 96 |
| 2023 Q1 | 37,418,446 | $117,492,869 | -$15,156,032 | $3.14 | 117 |
| 2022 Q4 | 39,224,213 | $231,404,815 | -$9,766,681 | $5.90 | 113 |
| 2022 Q3 | 39,456,577 | $346,000,579 | -$2,524,371 | $8.77 | 115 |
| 2022 Q2 | 39,425,650 | $297,247,580 | -$39,977,861 | $7.54 | 111 |
| 2022 Q1 | 37,306,180 | $904,604,832 | +$6,530,479 | $24.26 | 120 |
| 2021 Q4 | 35,893,940 | $1,154,835,979 | +$16,687,200 | $32.20 | 115 |
| 2021 Q3 | 34,491,766 | $1,542,710,693 | +$110,759,163 | $44.68 | 110 |
| 2021 Q2 | 31,945,852 | $1,209,520,921 | +$259,679,873 | $37.84 | 106 |
| 2021 Q1 | 25,097,387 | $926,788,055 | +$90,401,887 | $36.99 | 83 |
| 2020 Q4 | 22,706,689 | $743,535,975 | +$718,564,975 | $33.13 | 75 |